Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis

• 2022

  Log in to bookmark this resource.

  Log in
• Diana Bowser; Katharine Rowlands; Dhwani Hariharan; Raíssa Gervasio; Lauren Buckley; Yara Halasa-Rappel
PMID: 35968875DOI: https://dx.doi.org/10.1093/infdis/jiac172

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article presents a systematic review analyzing the economic impact of respiratory syncytial virus (RSV) infections on infants in the United States. Findings reveal that full-term infants account for the majority of RSV hospitalizations and costs, despite extremely premature infants incurring higher costs per hospitalization. The study shows that Medicaid covers a significant portion of RSV hospitalizations and costs, with Medicaid-insured infants more likely to be hospitalized for RSV treatment. Overall, infant RSV treatment costs amount to $709.6 million annually, with public sources shouldering over half of the financial burden, highlighting the substantial economic implications of RSV infections.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Child; Child, Preschool; Hospitalization; Infant; Medicaid; Respiratory Syncytial Virus Infections; United States; Databases, Factual; Insurance Coverage

Institutions: Brandeis University; Sanofi

---

More like this

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States 2022 · Sanofi, London School of Hygiene and Tropical Medicine, Brandeis University, London School of Hygiene & Tropical Medicine Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants 2023 · St. George's University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals Foundation NHS Trust, Sanofi, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris (AP-HP) Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month 2024 · Brown University, Sanofi, University of Groningen, Merative

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---